Tags: Drug.
S32212 is a drug which is under preclinical investigation as a potential antidepressant medicine. It behaves as a selective combined 5-HT2C receptor inverse agonist and α2-adrenergic receptor antagonist (at all three subtypes—α2A α2B and α2C) with additional 5-HT2A and to a lesser extent 5-HT2B receptor antagonistic properties and lacks any apparent affinity for the monoamine reuptake transporters or for the α1-adrenergic H1 or mACh receptors.
